Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 40

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 the Three Months Ended 

    June
    30, 2025  
    June
    30, 2024 
  
    Revenues 
    $297,500  
    $123,751 

    Cost of Sales 
     110,774  
     12,994 

    Total Operating Expenses 
     2,031,043  
     2,155,189 

    Total Other Income (Expense) 
     (466,720) 
     (2,631)

    Net Loss 
    $(2,311,037) 
    $(2,047,063)

    Net loss per share - basic and diluted 
    $(0.09) 
    $(0.11)

For
The Three Months Ended June 30, 2025, Compared to The Three Months Ended June 30, 2024

Total
Revenues. Revenues were $297,500 and $123,751 for the three months ended June 30, 2025 and 2024, respectively. Revenues in the
three months ended June 30, 2025, consist of sales of our Spryng® products of $148,243 and Precise PRP products of $149,257.
Revenues in the three months ended June 30, 2024, consisted of sales entirely of our Spryng® products of $123,751. The
increase in our revenues in the three months ended June 30, 2025, compared to the three months ended June 30, 2024, is due to sales of
Precise PRP products, pursuant to our exclusive licensing agreement with VetStem.

Cost
of Sales. Cost of sales were $110,774 and $12,994 for the three months ended June 30, 2025 and 2024, respectively. Cost of sales
includes product costs related to the sale of our Spryng® products, labor and overhead costs and product costs related
to the sale of Precise PRP products. The increase in our cost of sales in the three months ended June 30, 2025, compared to the three
months ended June 30, 2024, is due to sales of Precise PRP products.

Operating
Expenses. Operating expenses were $2,031,043 and $2,155,189 for the three months ended June 30, 2025 and 2024, respectively